

PUBLISHED VERSION

Amanda J. Page

Mimecan: a newly identified adipokine and regulator of appetite

EBioMedicine, 2015; 2(11):1584-1585

© 2015 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Originally published at:

<http://doi.org/10.1016/j.ebiom.2015.11.008>

PERMISSIONS

<http://creativecommons.org/licenses/by-nc-nd/4.0/>



Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

This is a human-readable summary of (and not a substitute for) the [license](#).

[Disclaimer](#)

You are free to:

Share — copy and redistribute the material in any medium or format

The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:



Attribution — You must give **appropriate credit**, provide a link to the license, and **indicate if changes were made**. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.



NonCommercial — You may not use the material for **commercial purposes**.



NoDerivatives — If you **remix, transform, or build upon** the material, you may not distribute the modified material.

No additional restrictions — You may not apply legal terms or **technological measures** that legally restrict others from doing anything the license permits.

15 March 2017

<http://hdl.handle.net/2440/103438>



Commentary

Mimscan: A Newly Identified Adipokine and Regulator of Appetite



Amanda J. Page *

Centre for Nutrition and Gastrointestinal Disease, Discipline of Medicine, University of Adelaide, Frome Road, Adelaide, SA 5005, Australia
 South Australian Health and Medical Research Institute, North Terrace, Adelaide, SA 5000, Australia
 Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia

ARTICLE INFO

Article history:

Received 19 October 2015

Received in revised form 3 November 2015

Accepted 3 November 2015

Available online 6 November 2015

Originally adipose tissue was considered a site of energy storage, providing mechanical as well as heat insulation and playing a role in the regulation of thermogenesis. However, since the discovery of Leptin in 1994 adipose tissue is now also recognised as an endocrine organ that produces a multitude of substances referred to as “adipokines”. These include adipolin, adiponectin, interleukin-6 (IL-6), leptin, omentin, tumour necrosis factor alpha (TNF α) and visfatin which play important roles in the regulation of food intake and metabolism (Smitka and Maresova, 2015). Adipose tissue is currently considered the largest endocrine organ secreting a multitude of hormones and cytokines known to affect processes both within the peripheral and central nervous system.

With respect to leptin and food regulation the adipose tissue acts as a ‘safety valve’ controlling the long term regulation of food intake. Leptin is released in proportion to the degree of adiposity and reduces food intake when energy reserves are sufficient. Unfortunately, in chronic high fat diet induced obesity the ‘safety valve’ malfunctions, with the occurrence of leptin resistance in the hypothalamus exacerbating the problem of obesity (Munzberg et al., 2004). Therefore, as a central target for the treatment of obesity, leptin and leptin analogues have proved disappointing as possible pharmacotherapies. The study by Cao et al. (2015) revealed that mimscan, first identified in the organic matrix of bovine bone, is also expressed in adipose tissue and is a potential target for the treatment of obesity. Cao et al. (2015) described mimscan as a satiety hormone with both intraperitoneal and intracerebroventricular injections suppressing food intake. Information on whether this is due to changes in meal size or meal frequency is unavailable but the cumulative effects of mimscan on food intake appear to be considerable.

DOI of original article: <http://dx.doi.org/10.1016/j.ebiom.2015.09.044>.

* Vagal Afferent Research Group, Centre for Nutrition and Gastrointestinal Diseases, South Australian Health and Medical Research Institute (SAHMRI), North Terrace, Adelaide, SA 5000, Australia.

E-mail address: Amanda.page@adelaide.edu.au.

Cao et al. (2015) demonstrated that the anorexic effects of mimscan are independent from leptin and melanocortin signalling with data showing a reduction in food intake still observed in obese leptin receptor knockout mice (db/db mice) and Agouti mice (A^{Y/a} mice) respectively. Cao et al. (2015) suggest mimscan-induced anorexia, within the central nervous system, is probably mediated via interleukin 1 β (IL-1 β) and IL-6. It is known that IL-6 production occurs selectively in microglia rather than astrocytes and primary hypothalamic neuronal cells and therefore the study by Cao et al. (2015) supports the emerging evidence for microglia mediated anorexic effects (Le Foll et al., 2015). Microglia and astrocytes may prove to be critical in appetite regulation within the central nervous system with the potential to be new novel targets for the treatment of obesity.

There are still many questions to be answered before the importance of mimscan in food intake and appetite regulation can be determined. These include translation of findings in the mouse to the human and establishment of the effectiveness of mimscan on food intake in high fat diet induced obesity. For instance, leptin is effective at reducing food intake in leptin knockout mice (ob/ob mice) (Halaas et al., 1995) and also obese humans with defective leptin production (Paz-Filho et al., 2011). It is only in diet-induced obese conditions that leptin resistance is observed. It is therefore essential to establish the effectiveness of mimscan at reducing food intake in high fat diet induced obese mice. In addition, although the effect of mimscan on food intake is promising there appears to be desensitisation to mimscan over treatment days raising some doubts on the usefulness of mimscan as a pharmacotherapy for obesity.

Cao et al. (2015) reason that, as lower concentrations of mimscan were required to elicit an anorexic effect via intracerebroventricular compared to intraperitoneal injections, mimscan is acting centrally. They discount any possible peripheral effect. It would be useful to know the circulating levels of mimscan after intraperitoneal injections in addition to the clearance rates. It is known that numerous adipokines are expressed in other peripheral regions associated with satiety signalling, such as the gastrointestinal tract. For example, leptin is not only expressed in adipose tissue but also the stomach where it modulates vagal afferent satiety signals (Kentish et al., 2013). Cao et al. (2015) demonstrated that mimscan is expressed in other organs and tissue such as the lungs but did not look at expression in the gastrointestinal tract where the short term regulation of food intake and meal size is initiated. It would be interesting to see if specific regions within the gastrointestinal tract express mimscan.

In conclusion, mimosin is an adipokine hormone that induces anorexia centrally by increasing IL-1 β and IL-6 in the hypothalamus. The role mimosin plays in the regulation of food intake in high fat diet induced obesity and the therapeutic potential of mimosin or analogues of mimosin in the treatment of obesity remains to be determined.

The author declares no conflict of interest.

References

- Cao, H.-M., Ye, X.-P., Jiang, H., Ma, J.-H., Li, S.-X., Li, R.-Y., Li, X.-S., Guo, C.-C., Wang, Z.-Q., Zhan, M., Zuo, C.-L., Pan, C.-M., Zhao, S.-X., Zheng, C.-X., Song, H.-D., 2015. Mimosin, a novel satiety hormone abundantly expressed in adipose tissue. *EBioMedicine* 2, 1718–1724.
- Halaas, J.L., Gajiwala, K.S., Maffei, M., Cohen, S.L., Chait, B.T., Rabinowitz, D., Lallone, R.L., Burley, S.K., Friedman, J.M., 1995. Weight-reducing effects of the plasma protein encoded by the obese gene. *Science* 269, 543–546.
- Kentish, S.J., O'Donnell, T.A., Isaacs, N.J., Young, R.L., Li, H., Harrington, A.M., Brierley, S.M., Wittert, G.A., Blackshaw, L.A., Page, A.J., 2013. Gastric vagal afferent modulation by leptin is influenced by food intake status. *J. Physiol.* 591, 1921–1934.
- Le Foll, C., Johnson, M.D., Dunn-Meynell, A.A., Boyle, C.N., Lutz, T.A., Levin, B.E., 2015. Amylin-induced central IL-6 production enhances ventromedial hypothalamic leptin signaling. *Diabetes* 64, 1621–1631.
- Munzberg, H., Flier, J.S., Bjorbaek, C., 2004. Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. *Endocrinology* 145, 4880–4889.
- Paz-Filho, G., Wong, M.L., Licinio, J., 2011. Ten years of leptin replacement therapy. *Obes. Rev. Off. J. Int. Assoc. Study Obes.* 12, e315–e323.
- Smitka, K., Maresova, D., 2015. Adipose tissue as an endocrine organ: an update on pro-inflammatory and anti-inflammatory microenvironment. *Prague Med. Rep.* 116, 87–111.